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ABSTRACT
Objectives: To establish the prevalence of cervical cytology abnormalities, determine 
the correlation between CD4+ cell count and abnormal Pap smear, determine the 
correlation between WHO-HIV staging and abnormal pap smear among HIV infected 
women attending HIV clinic at Rwanda Military Hospital.
Design: Cross-sectional descriptive study
Setting: Rwanda Military Hospital Kigali, Rwanda
Subjects: All HIV-positive women, 18-69 years who had been or were sexually active 
and were attending the HIV-clinic and consented to participate in the study.
Results: Two hundred and ninety three women infected with HIV had cervical smear 
taken for cytology. Of the 293 women who were recruited for the study, cervical 
Squamous Intra epithelial Lesion (SIL) were present in 58 (20%). Of those with cervical 
SIL, 33 (56.89%) women had low-grade SIL, 15(25.86%) had Atypical Squamous Cells 
of Undetermined Significance (ASCUS), six (10.34%) had high-grade SIL, three (5.17%) 
had Squamous cell carcinoma ( SCC) and one (1.72%) had Atypical Glandular Cells 
of Undetermined Significance (AGUS). In the current study, use of ARV drugs was 
not associated with a reduction in the risk of cervical SIL 
Conclusion: A high prevalence of cervical SIL was found among HIV-infected women at 
Rwanda Military Hospital. Increased immune suppression was significantly associated 
with cervical SIL.  
INTRODUCTION
Cervical cancer is the second most common cancer in 
women worldwide, and the seventh most common 
overall (in both sexes combined). In developing 
countries however, cancer of the uterine cervix is 
ranked second to cancer of the breast, whereas in 
developed countries cervical cancer is ranked fifth 
(1). Worldwide, cervical cancer accounts for almost 
half a million (529,800) new cases annually of all 
cancers diagnosed in women. More than 85% of the 
global burden occurs in developing countries, where 
it accounts for 13% of all female cancers (2). 
 The incidence of the cervical cancer incidence 
in  East African countries is (34.5/100,000 women/
year) (2).
 Annually, cervical cancer is responsible for 
275,100 deaths, about 88% of which occur in 
developing countries: 53 000 in Africa, 31 700 in Latin 
America and the Caribbean, and 159 800 in Asia (1, 
2). Invasive cancer of the cervix is considered to be 
a preventable condition, given that it is associated 
with a long pre-invasive stage, making it amenable 
to screening and treatment as long as it is detected 
early and managed effectively (4,5). 
 Cancer of the cervix has been classified as an 
acquired immune deficiency syndrome (AIDS) 
defining cancer by the US Centers for Disease Control 
and Prevention (6). 
 As more women contract the virus, the risk of 
cervical squamous intra-epithelial lesions (SIL) or 
cervical intra-epithelial neoplasia and ultimately 
cervical cancer increases (7).
 Human papillomavirus (HPV) is known to play 
an important etiological role in the development of 
cervical cancer. HPV genotypes that have only rarely 
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or not been found in invasive cancer of the cervix are 
defined as low risk types they include HPV 6 and 
HPV 11. High-risk types, such as HPV (16, 18, 45, 31, 
33, 45, 52, 58, 35, and 51) are among most common 
types found in invasive cervical cancers and are the 
main factors implicated in cervical carcinogenesis (8).
 Factors that contribute to the development or 
cervical cancer after infection with HPV include 
immunosupression.  Immunosuppression by HIV 
infection is a strong risk factor for abnormal cytology 
(SIL). Immunocompromised individuals such as 
transplant recipients and human immunodeficiency 
virus-infected individuals are more prone to HPV 
infections and HPV-associated diseases (9). 
 In immunocompetent individuals, HPV 
infections normally clear in six to twenty-four months 
in 70% of females (10). The natural history of HPV 
infection is altered in persons infected with the 
human immunodeficiency virus (HIV) and there is 
an increased likelihood of persistent HPV infections 
in this population. This persistent infection increases 
their risk of having cervical dysplasia and cervical 
intraepithelial neoplasms (CIN). 
 Primary prevention of cervical cancer involves 
prevention of HPV infection. Preventing HPV 
infection is important in preventing cervical cancer 
because almost all cervical cancer cases are caused 
by HPV, a virus transmitted through sexual contact 
(11). Primary prevention can be achieved through; 
Behavioural change approaches and the use of 
biological mechanisms, including HPV vaccination 
(Gardasil and Cervirex). 
 Secondary prevention aims at preventing 
invasive cervical cancer by detecting and treating pre-
cancerous lesions of the cervix before they progress 
to cancer. Cervical cancer is the most effectively 
controlled by screening  through cervical cytology 
(pap smear) compared to other cancers because pre-
cancerous lesions are detected and treated (3). 
MATERIALS AND METHODS
The study was done at Rwanda Military Hospital. 
Rwanda Military Hospital is the largest Hospital 
located in Kicukiro District of Kigali city. Consent 
was obtained from all participants and no incentives 
were given to study the subjects. The sample size 
was 293. The study population comprised of all HIV-
positive women, 18-69 years who had been or were 
sexually active and were attending the HIV-clinic and 
consented to participate in the study.
 Women on their routine follow up for HIV who 
met the inclusion criteria and consented to participate 
in the study were screened for cervical cancer using 
conventional pap smear. Pregnant and post-natal 
mothers were excluded from our study.
 Study participants from their routine HIV clinic 
were referred to the study room, the study was 
explained to them, those who were found to be eligible 
and were willing to participate in the study were 
recruited. The data were coded and were analysed 
using EPI info version 6.
RESULTS
A total of 293 women were enrolled in the study. 
The mean age of our participants was 36.3 (SD 8.2). 
Youngest was 19 years and the oldest was 59 years. 
Majority of the women 127 (43.3%) were aged between 
30-39 years. Majority of our study participants 
257(87.7%) had sexual debut after 16 years  with a 
mean age at sexual debut of 18.9.  Most participants 
251(85.7%) in our study had more than one sexual 
partner  and those who had more than four lifetime 
sexual partners were the majority155 (52.9%). Majority 
of the patients 225(76.8%) were on follow up for more 
than four years and 171(58.4%) were on follow up for 
more than six years.
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Table 1
Socio-Demographic Characteristics
Factor N % (95% CI) Mean (SD)
Age    
< 20 1 0.3 (0.0 - 1.0)
20  - 29 68 23.2 (18.3 - 28.1)
30 – 39 127 43.3 (37.6 - 49.1) 36.3 (8.2)
40 – 49 78 26.6 (21.5 - 31.7)
50  - 59 19 6.5 (3.6 - 9.3)
Total 293   
Age at 1st Sexual Intercourse    
< 16 36 12.3 (8.5 - 16.1)
16+ 257 87.7 (83.9 - 91.4) 18.9 (3.6)
Total 293   
Number of lifetime Sexual Partners.    
1 42 14.3(10.3 - 18.4)
2-3 96 32.8 (27.4 - 38.2) 4.2 (3.8)
4 + 155 52.9 (47.2 - 58.7)
Total 293
Duration since diagnosis of HIV (yrs)    
< 1 5 1.7 (0.2 - 3.2)
2-3 63 21.5 (16.8 - 26.2)
4-5 54 18.4 (13.9 - 22.9) 6.9 (4.0)
6+ 171 58.4 (52.7 - 64.0)
Total 293   
Ever Been screened for 
Cancer of the cervix.    
Yes 2 0.7 (0.0 - 1.6)
No 291 291 (99.3 - 100.0) -
Total 293   
Only two out of 293 patients had had cervical cancer screening done prior to this research and neither of 
two knew about her results.
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Table 2
Clinical findings
Finding N % (95% CI) Mean (SD)
Initial CD4 Count   
< 200 143 48.8 (42.8 - 54.7) 223 (162)
200 + 150 51.2 (45.3 - 57.2)
Total 293   
Current CD4 Count   
< 200 21 7.2 (2.7 - 7.9) 497 (209)
200 + 272 92.8 (92.0 - 97.3)
Total 293   
WHO Staging    
I 217 74.1 (69.0 - 79.1)
II 31 10.6 (7.0 - 14.1)
III 37 12.6 (8.8 - 16.5) -
IV 8 2.7 (0.9 - 4.6)
Total 293   
On ART
Yes 284 96.9 %
No 9 3.1 %
Total 293  
 
The mean CD4 count was 223 (SD 162) at the beginning 
of follow up with 143 (48.8%) patients having CD4 
count less than 200/mm3 and the current mean CD4 
count was 497 (SD 209) with only 21 (7.2%) having 
CD4cell count less than 200/mm3.
Majority of our patients 217 (74.1%) in this study were 
in WHO HIV/AIDS class 1 at the time of the study. 
Most of the patients 284 (96.9%) were on HAART 
during the time of the study.
Figure 2
Prevalence of abnormal cytology
Abnormal smear Negative for intra-epithelial lesion Inadequate smear
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Figure 3
Bethesda classification N=58% 
Cervical cytology abnormality
LSIL was the most common lesion seen among the abnormal Pap smears.
Table 3











8 13.8 13 5.7
> 200 cells/
mm³
50 86.2 217 94.3 0.033 2.7(1.1-6.8)
Women whose current CD4+ cell count was less than 200 cells/mm³ were 2.7 times more likely to have 
abnormal pap smear than women whose current CD4+cell count was above 200 cells/mm³ [Odds ratios 
(OR) = 2.7,95% CI (1.1-6.8)]. P = 0.033
Table 4
WHO-HIV classification and abnormal smear, N=288, P Value = 0.705
Freq % Freq %
Who-HIV classification i. 46 79.3 168 73.0
II. 6 10.3 24 10.4
III. 5 8.6 32 13.9
IV. 1 1.7 6 2.6
Negative for  intraepithelial lesionAbnormal cytology
A total of 293 women were enrolled in the study. Five 
were excluded from the analysis due to inadequate 
smear or missing cervical cells at all.
 The prevalence of cervical cytology abnormalities 
in this research was 58 out of 288 (20%) with LSIL being 
the most prevalent at 33 out of 288 (11.30%), ASCUS 
15 out of 288 (5.13%), HSIL 6 out of 292 (2.05%), SCC 
was seen in 3 out of 288 (1.02%) and lastly AGC-H 
was 1 out of 288 (0.34%).
ASCUS AGC-H LSIL HSIL SCC
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The association between WHO-HIV classification and abnormal Pap smear was not found to be statistically 




p-value OR (95% CI)
Freq % Freq %   
Age
< 30 15 25.9 53 23.0
30+ 43 74.1 177 77.0 0.851 1.2 (0.6 - 2.3)
 On ART       
       Yes 54 93.1 225 97.8
       No 4       6.9 5 2.2 0.065 0.3 (0.1 - 1.2)
Age at first sexual intercourse       
< 16 7 12.1 29 12.6
16+ 51 87.9 201 87.4 0.912 0.9 (0.4 - 2.3)
No. of Sexual Partner       
1 7 12.1 35 15.2
1+ 51 87.9 195 84.8 0.544 0.8 (0.3 - 1.8)
Duration since diagnosis       
1 - 3 11 19.0 54 23.5
4+ 47 81.0 176 76.5 0.462 0.8 (0.4 - 1.6)
There was no statistically significant association 
between the variables in the table above (Table 5) 
and abnormal Pap smear. 
DISCUSSION
During the early days of the HIV epidemic, HIV-
infected women who had cervical human papilloma-
virus infection and SIL frequently died of AIDS well 
before developing invasive cervical cancer (12). 
However, following the introduction of HAART, 
the clinical course of HIV has been substantially 
prolonged, making HIV-infected women a clinically 
significant group of patients who have an increased 
risk of acquiring human papillomavirus infection 
and developing SIL and invasive cervical cancer (13).
 According to the World Health Organization 
(WHO), invasive cervical cancer (ICC) is the second 
most common cancer in women worldwide and is 
more frequent in low income countries (14). Recent 
guidelines recommend that, following two initial 
normal Pap-smears at a six month interval, all HIV-
positive women should undergo annual cervical 
cytologic examination. In addition, it is recommended 
that all immunosuppressed women with atypical 
squamous cells undergo colposcopy (15). This study 
provides the first comprehensive analysis of the 
prevalence of cervical cytological abnormalities in 
this population at Rwanda Military Hospital.
 The prevalence of cervical cytology abnormalities 
in our study was (20%) 58/288, (Figure 1). This is 
comparable to 21.3%(60/280) as documented in the 
study done in Thailand by Pimpika Tansupswatdikul, 
Somkid Piyaman MD et al in 2009 which was aimed at 
establishing prevalence of abnormal cervical cytology 
from Pap smear in HIV-infected women (16). 
 The reported prevalence in this study is however 
higher than the 2.9% and 13.3%, 10.9% reported by 
Kapiga et al (17) among HIV-seropositive pregnant 
women in Tanzania, Chalermchockcharoenkit et al 
in Thailand and Anorlu in Nigeria (18, 19) among 
HIV-infected women by postpartum Papanicolaou 
smear. 
 However, other researchers have reported higher 
prevalences in Africa involving HIV-positive women; 
In Makurdi, Nigeria (57.7%) (12), Tanzanian 28 % (20) 
and South African 31% (21), Kenya (46%) (22).
 The prevalence of cervical cytology in the 
Rwandan general population in not known but the 
World Health Organization ranks Rwanda among 
the countries worldwide with the highest cervical 
Positive Negative
Results
October 2014 East african MEdical Journal    339
cancer incidence, estimated at 34.5/100,000 (IARC 
2008). 
CD4 Cell count: Immunosuppression by HIV infection 
is a strong risk factor for abnormal cytology (SIL). 
In this study, 48.8% of HIV-positive women had 
baseline CD4 counts less than 200 cells/mm3, which 
is diagnostic of immunologic AIDS. Prolonged CD4 
lymphopenia in patients infected with HIV results in 
defective T-cell proliferation regardless of the current 
CD4 count or viral load (23). Davis et al reported that 
the strongest predictor of genital dysplasia was a 
nadir CD4 and CD4 count less than 200 cells/mm³ (7). 
 The effect of HAART on the prevalence of SIL 
has not been significant or it has remained unchanged 
(24). Similarly in this study, the use of HAART was 
not associated with a significant reduction in the risk 
of SIL.
In conclusion, a high prevalence (20%) of cervical 
cytology abnormality was found among HIV infected 
women at Rwanda Military Hospital, Rwanda. 
Decreased CD4 cell counts were associated with 
abnormal Pap smear. CD4 cell counts less than 200 
cells/mm3 was significantly associated with positivity 
of the cervical cytology. There was no statistically 
significant association between WHO stage and 
abnormal Pap smear. 
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